NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Piperacillin、Tazobactam市場分析 (2021年∼2025年)

Investigation Report on China's Piperacillin and Tazobactam Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008270
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Piperacillin、Tazobactam市場分析 (2021年∼2025年) Investigation Report on China's Piperacillin and Tazobactam Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

Piperacillin和Tazobactam1996年在中國核可,2009年納入中國國家醫療保險。。2020年終時,中國的Piperacillin Sodium、Tazobactam Sodium市場有20個以上的廠商進入,其中Pfizer Ltd佔最大的市場佔有率。

中國國內的Piperacillin、Tazobactam的銷售量,從2016年到2020年以3.28%的年複合成長率擴大,2020年達14億3600萬人民幣。但,由於新型冠狀病毒感染疾病 (COVID-19)的影響當下有縮小趨勢。今後,若COVID-19的影響階段性緩和,市場規模將再次踏實擴大。

本報告提供中國的Piperacillin、Tazobactam的市場相關分析,產品的概要和授權情形,整體市場規模趨勢預測,各地區的詳細趨勢,市場價格趨勢預測 (2016年∼2020年/2021年∼2025年),主要企業的簡介與市場佔有率,主要的推動及阻礙市場要素等資訊彙整,為您概述為以下內容。

目錄

第1章 Piperacillin、Tazobactam的相關概念

  • Piperacillin、Tazobactam的適應症
  • 中國國內的Piperacillin、Tazobactam的開發趨勢
  • 中國政府的Piperacillin、Tazobactam的核準情況
  • COVID-19對中國的Piperacillin、Tazobactam銷售的影響

第2章 中國國內的Piperacillin、Tazobactam銷售趨勢 (2016年∼2020年)

  • Piperacillin、Tazobactam的銷售額
    • 整體銷售額
    • 各地區的銷售額
  • Piperacillin、Tazobactam的銷售量
    • 整體銷售量
    • 各地區的銷售量
  • 中國國內的Piperacillin、Tazobactam銷售趨勢:各劑型 (2016年∼2020年)
    • 注射劑
    • 其他的劑型

第3章 中國的Piperacillin、Tazobactam主要製造商分析 (2016年∼2020年)

  • 主要Piperacillin、Tazobactammeka的市場佔有率分析
    • 市場佔有率:銷售額為基礎
    • 市場佔有率:銷售量為基礎
  • Pfizer Ltd
    • 企業簡介
    • 中國的Piperacillin、Tazobactam銷售趨勢
  • Zhuhai Lianbang Pharmaceutical Factory Co., Ltd. Zhongshan Branch
  • Shangdong Anxin Pharmaceutical Co.,Ltd.
  • North China Pharmaceutical Company Ltd.
  • Reyoung Pharmaceutical Co., Ltd.

第4章 中國的Piperacillin、Tazobactam的價格趨勢:各主要製造商 (2020年∼2021年)

  • Pfizer Ltd (TAZOCIN)
  • Zhuhai Lianbang Pharmaceutical Factory Co., Ltd. Zhongshan Branch (Lianbangtazuoxian)
  • Shangdong Anxin Pharmaceutical Co., Ltd.
  • North China Pharmaceutical Company Ltd. (Paitaqiang)
  • Reyoung Pharmaceutical Co., Ltd. (Beifubao)

第5章 中國的Piperacillin、Tazobactam市場未來展望 (2021年∼2025年)

  • 左右中國的Piperacillin、Tazobactam市場趨勢的要素
    • COVID-19對中國的Piperacillin、Tazobactam市場的影響
    • 市場促進因素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105505

Piperacillin and Tazobactam is a compound anti-infective drug composed of piperacillin (semi-synthetic penicillin antibiotic) and tazobactam (B-lactamase inhibitor). It is suitable for moderate and severe infections which are resistant to piperacillin, caused by beta-lactamase-producing bacteria that are sensitive to piperacillin and tazobactam. Piperacillin and Tazobactam were jointly developed by Pfizer, Wyeth, and Taisho Corporation of Japan. Piperacillin and tazobactam were approved in China in 1996 and were included in the national medical insurance in China in 2009. As of the end of 2020, there are more than 20 manufacturers in the piperacillin sodium and tazobactam sodium market in China, of which Pfizer Ltd has the largest market share.

According to CRI's market research, the sales of Piperacillin and Tazobactam in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the new crown epidemic on the overall medical diagnosis and treatment services, the sales decreased from CNY1.681 billion in 2019 to CNY1.436 billion in 2020, with a year-on-year decrease of 14.6%. The CAGR of sales of piperacillin sodium and tazobactam sodium from 2016 to 2020 is 3.28%.

CRI predicts that the sales of Piperacillin and Tazobactam will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. In addition, Piperacillin/Tazobactam has good clinical effects and few adverse reactions. Piperacillin/Tazobactam is more effective and safer for the treatment of lower respiratory tract infections and urinary tract infections caused by beta-lactamase-producing strains compared with similar drugs. Based on these advantages, the sales of piperacillin and tazobactam will increase steadily in the future.

Topics Covered:

  • The impact of COVID-19 on China's Piperacillin and Tazobactam market
  • Sales value of China's Piperacillin and Tazobactam 2016-2020
  • Competitive landscape of China's Piperacillin and Tazobactam market
  • Prices of Piperacillin and Tazobactam in China
  • Prices of Piperacillin and Tazobactam in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Piperacillin and Tazobactam market
  • Prospect of China's Piperacillin and Tazobactam market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Piperacillin and Tazobactam

  • 1.1 Indications for Piperacillin and Tazobactam
  • 1.2 Development of Piperacillin and Tazobactam in China
  • 1.3 Governmental Approval of Piperacillin and Tazobactam in China
  • 1.4 The Impact of COVID-19 on Piperacillin and Tazobactam sales in China

2 Sales of Piperacillin and Tazobactam in China, 2016-2020

  • 2.1 Sales Value of Piperacillin and Tazobactam
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Piperacillin and Tazobactam
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Piperacillin and Tazobactam by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Form

3 Analysis of Major Piperacillin and Tazobactam Manufacturers in China in 2020

  • 3.1 Analysis of Market Share of Major Piperacillin and Tazobactam Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Pfizer Ltd
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of TAZOCIN (Pfizer Ltd's Piperacillin and Tazobactam) in China
  • 3.3 Zhuhai Lianbang Pharmaceutical Factory Co., Ltd. Zhongshan Branch
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Lianbangtazuoxian (Zhuhai Lianbang Pharmaceutical Factory Co., Ltd. Zhongshan Branch's Piperacillin and Tazobactam) in China
  • 3.4 Shangdong Anxin Pharmaceutical Co.,Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Shangdong Anxin Pharmaceutical Co.,Ltd.'s Piperacillin Sodium/ Tazobactam Sodium in China
  • 3.5 North China Pharmaceutical Company Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Paitaqiang (North China Pharmaceutical Company Ltd.'s Piperacillin and Tazobactam) in China
  • 3.6 Reyoung Pharmaceutical Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Beifubao (Reyoung Pharmaceutical Co., Ltd.'s Piperacillin and Tazobactam) in China

4 Prices of Piperacillin and Tazobactam for Different Manufacturers in China, 2020-2021

  • 4.1 Pfizer Ltd (TAZOCIN)
  • 4.2 Zhuhai Lianbang Pharmaceutical Factory Co., Ltd. Zhongshan Branch (Lianbangtazuoxian)
  • 4.3 Shangdong Anxin Pharmaceutical Co., Ltd.

4.4North China Pharmaceutical Company Ltd. (Paitaqiang)

  • 4.5 Reyoung Pharmaceutical Co., Ltd. (Beifubao)

5 Prospect of Chinese Piperacillin and Tazobactam Market, 2021-2025

  • 5.1 Influential Factors of Chinese Piperacillin and Tazobactam Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Piperacillin and Tazobactam Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Piperacillin and Tazobactam Injection Registration in China
  • Chart Sales Value of Piperacillin and Tazobactam Injection over the World
  • Chart Sales Value of Piperacillin and Tazobactam Injection in China, 2016-2020
  • Chart Sales Value of Piperacillin and Tazobactam Injection in China by Region, 2016-2020
  • Chart Sales Volume of Piperacillin and Tazobactam Injection in China, 2016-2020
  • Chart Sales Volume of Piperacillin and Tazobactam Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Piperacillin and Tazobactam Injection Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of TAZOCINin China, 2016-2020
  • Chart Sales Value and Volume of Lianbangtazuoxian in China, 2016-2020
  • Chart Sales Value and Volume of Shangdong Anxin Pharmaceutical Co., Ltd.'s Piperacillin and Tazobactam Injection in China, 2016-2020
  • Chart Sales Value and Volume of Paitaqiang in China, 2016-2020
  • Chart Sales Value and Volume of Beifubao in China, 2016-2020
  • Chart Referential Prices of TAZOCIN in China by Region, 2020-2021
  • Chart Referential Prices of Lianbangtazuoxian in China by Region, 2020-2021
  • Chart Referential Prices of Shangdong Anxin Pharmaceutical Co., Ltd.'s Piperacillin and Tazobactam Injection in China by Region, 2020-2021
  • Chart Referential Prices of Paitaqiang in China by Region, 2020-2021
  • Chart Referential Prices of Beifubao in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Piperacillin and Tazobactam Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Piperacillin and Tazobactam Injection in China, 2021-2025